StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO – Get Rating) in a note issued to investors on Tuesday. The firm set a “sell” rating on the medical device company’s stock.
NeuroMetrix Price Performance
Shares of NASDAQ:NURO opened at $1.09 on Tuesday. NeuroMetrix has a one year low of $0.93 and a one year high of $4.73. The company has a 50 day moving average of $1.33 and a 200-day moving average of $1.55. The stock has a market cap of $8.54 million, a price-to-earnings ratio of -1.58 and a beta of 2.29.
NeuroMetrix (NASDAQ:NURO – Get Rating) last issued its quarterly earnings data on Thursday, February 23rd. The medical device company reported ($0.09) earnings per share (EPS) for the quarter. The firm had revenue of $1.85 million for the quarter. NeuroMetrix had a negative net margin of 65.54% and a negative return on equity of 22.18%.
Hedge Funds Weigh In On NeuroMetrix
NeuroMetrix, Inc engages in the development and manufacture of diagnostic and therapeutic neurostimulation-based medical devices. Its products include DPNCheck, Quell, and ADVANCE system. It also focuses on the sale of medical equipment and consumables. The company was founded by Shai N. Gozani in June 1996 and is headquartered in Woburn, MA.
- Get a free copy of the StockNews.com research report on NeuroMetrix (NURO)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for NeuroMetrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroMetrix and related companies with MarketBeat.com's FREE daily email newsletter.